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A deeper understanding of the gut-brain axis is of significance in pediatrics, given the 
influential role of early childhood experiences and exposures in shaping the microbiome, and 
health, across the life course. This systematic review synthesized evidence on the connection 
between the gut microbiome and mental health in children with physical illness. Six 
electronic databases were systematically searched and data extracted according to the 
Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines. 
Of 1,476 identified articles, 11 articles reporting on 9 unique studies (all randomized 
controlled trials) were included. Most studies examined the gut microbiome in infants with 
colic, while the remaining studies investigated outcomes in children aged 1 day to 18 years 
at-risk for atopic dermatitis or irritable bowel syndrome. Baseline and post-intervention gut 
microbiome differences varied across studies. Findings on psychological functioning also 
varied, with only half of the captured studies showing a positive effect of intervention on 
psychological wellbeing. Only two studies analyzed the association between the gut 
microbiome and psychological outcomes; each with a different pattern of results. As the field 
moves forward, it will be critical to gain a better understanding of the microbiome 
characteristics that influence mental health outcomes in pediatric populations.  
 





Children with critical or chronic illness can experience a range of stressors, including 
invasive treatments and side effects, periods of hospitalisation and prolonged medical care, 
changes to academic and social schedules, shifts in family dynamics, and fear and uncertainty 
about the future (Tapanes, Distelberg, Williams-Reade, & Montgomery, 2015). The multiple 
systems that children are embedded within are often disrupted during illness, altering the 
typical course of development, which can further exacerbate symptoms and their 
consequences (Wood, 1993).  
 
Thus, it is unsurprising that many medical conditions are associated with poorer quality of 
life (QOL) and aberrant emotional and behavioral outcomes in children (Hysing, Elgen, 
Gillberg, Lie, & Lundervold, 2007; Hysing, Elgen, Gillberg, & Lundervold, 2009; Pinquart & 
Shen, 2011). Children with complex congenital heart disease, for example, have a heightened 
risk of neurodevelopmental impairment, internalizing and externalizing disorders, and poorer 
health-related QOL compared to healthy, typically-developing children (Denniss, Sholler, 
Costa, Winlaw & Kasparian, 2018; Kasparian, Winlaw & Sholler, 2016; Tesson et al., in 
press), and this pattern is found across a range of disease groups (Greenley et al., 2010; 
Mackner & Crandall, 2007; Varni, Limbers, & Burwinkle, 2007). While this has potentially 
negative implications for child wellbeing, it can also be viewed as an opportunity to enhance 
the psychosocial context and improve pediatric outcomes. Psychological interventions for 
children with functional gastrointestinal disorders, for example, have been shown to improve 
physical health outcomes (Brent, Lobato, & LeLeiko, 2009; Levy et al., 2010, 2013). 
 
To further improve clinical care and QOL in pediatric populations, it is critical we develop a 
deeper understanding of the biological and psychosocial mechanisms underlying poor mental 
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health outcomes. One biological system receiving substantial attention from the fields of 
medicine and psychology is the gastrointestinal system. There is mounting evidence that the 
gut microbiome (i.e., the vast and diverse array of microorganisms residing in the 
gastrointestinal tract, and their collective genomes) contributes to both physical and mental 
health (Callaghan, 2017; Cho & Blaser, 2012; Cowan et al., 2018; Cowan & Richardson, in 
press; Dinan & Cryan, 2017; Kinross, Darzi, & Nicholson, 2011; Sarkar et al., 2018). 
Preclinical models provide causal evidence that the gut microbiome affects emotional 
development. Germ-free mice born and raised in the absence of any microorganisms, for 
example, exhibit atypical social and emotional behavior (Arentsen, Raith, Qian, Forssberg, & 
Heijtz, 2015; Clarke et al., 2012; Davis, Bryda, Gillespie, & Ericsson, 2016; Heijtz et al., 
2011; Hoban et al., 2017), alongside physiological markers of anxiety, depression and stress 
reactivity (Erny et al., 2015; Luczynski et al., 2016; Neufeld, Kang, Bienenstock, & Foster, 
2011; Sudo et al., 2004). Correlational studies in adult humans show that individuals with a 
range of physical and mental health difficulties – from depression and autism spectrum 
disorder to Parkinson’s disease, irritable bowel syndrome (IBS), stroke and cancer – have 
different microbial profiles compared to healthy peers (Jiang et al., 2015; Parracho, Bingham, 
Gibson, & McCartney, 2005; Scheperjans et al., 2015; Schwabe & Jobin, 2013; Yin et al., 
2015; Zheng et al., 2016).  
 
In children, emerging research is identifying similar disruptions to the microbiome and gut 
development across a range of health conditions, including asthma, IBS, inflammatory bowel 
disease, cystic fibrosis, and infant colic (Johnson & Versalovic, 2012; Nielsen et al., 2016; 
O’Mahony, Stilling, Dinan, & Cryan, 2015; Slattery, MacFabe, & Frye, 2016). Studies 
investigating the link between the gut microbiome and neurodevelopmental outcomes are 
much more limited, but preliminary studies have observed associations between the early 
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microbiome and cognitive and emotional development in healthy infants (Carlson et al., 
2018; Christian et al., 2015). Mounting research indicates gut microbiome composition is 
associated with autism, a neurodevelopmental disorder (Vuong & Hsiao, 2017). Such 
outcomes highlight the overlap between gut microbiome maturation and critical periods of 
neurodevelopment. Indeed, the instability and immaturity of the gut microbiome from 
infancy to adolescence means it is more vulnerable to environmental insults, such as 
antibiotic use, stress and infection, all of which may lead to dysbiosis and poorer 
neurodevelopmental outcomes (Clarke, Mahoney, Dinan, & Cryan, 2014; Codagnone et al., 
in press). Given many pediatric populations are exposed to such environmental insults, 
further research on how the microbiome affects brain development and mental health is of 
importance if we are to improve child outcomes. 
 
Associations between the microbiome and physical and mental health are further supported 
by evidence that probiotics (i.e., beneficial bacterial strains) may improve physical symptoms 
and health-related QOL in pediatric populations (Guandalini et al., 2010; Horvath, 
Dziechciarz, & Szajewska, 2011; Sung et al., 2018); however, studies in this area often do not 
measure the direct impact of intervention on the gut microbiome. This represents an 
important gap in our understanding of the mechanisms underlying probiotic treatment effects 
which in turn hinders the implementation of such treatments in clinical practice due to 
uncertainties regarding who will benefit and under what circumstances. To clarify the current 
state of the science and shed light on potential microbiome mechanisms, this systematic 
review aimed to synthesize and critically appraise all available evidence on the connection 







Data search strategy and sources 
The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines (Moher, Liberati, Tetzlaff, Altman, & Group, 2009) were used to identify, screen 
and extract data from identified articles. A systematic search was carried out in April 2018 
using six electronic databases (MEDLINE, Embase, PsycINFO, the Cumulative Index to 
Nursing and Allied Health Literature, EMcare, Scopus). The search strategy was developed 
in MEDLINE and adapted for use in each database. A string of key terms was combined for 
each search, including: child, medical illness, disease, microbiome, microbiota, dysbiosis, 
psychological stress, and quality of life (search strategy available on request). Date range 
restrictions were not applied to maximize the number of articles returned. Ancestry methods, 
citation chaining and prolific author searching in Scopus were used to identify additional 
articles. Auto-alerts were created using the same unique search algorithm for each database, 
with findings incorporated into the review until June 30, 2018.  
 
Study selection criteria  
Studies were eligible for review if they: (i) Examined infants, children, or young people aged 
0-18 years with a physical health condition; (ii) Measured the composition or diversity of the 
gut microbiome or its constituents; and (iii) Assessed mental health or illness, QOL, or any 
form of psychosocial functioning of the child or young person, as determined by parent- or 
self-report (e.g., frequency of crying in infants). Studies examining outcomes in both children 
and adults were included only if child outcomes were reported separately. Articles were 
excluded if they investigated non-human animals, reported on qualitative data, or were 
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systematic reviews, case studies, conference abstracts, dissertations, commentaries or 
editorials, or published in a non-English language.  
 
Initially, titles were screened by one author (JK) to determine eligibility. Abstracts and full-
texts were independently screened for eligibility by two authors (JK, NAK). Conflicts of 
opinion were resolved through consensus or consultation with a third reviewer (CYO). 
Article full-texts deemed eligible for review (or for which eligibility could not be determined 
from the title or abstract) were retrieved for data extraction. While review articles were 
excluded from analysis, these were collected and screened to ensure originality of the review 
concept. No published reviews of a similar nature to the present study were identified. 
  
Data extraction 
Data extraction was undertaken by two authors (JK, CSMC) using a standardized data 
collection form, and checked for accuracy by a third author (CYO). Extracted data included: 
study characteristics (e.g., authors, country, research design), sample characteristics (e.g., 
sample size, age, medical condition), study methods (e.g., techniques and measures to assess 
the gut microbiome and psychosocial functioning) and results, as relevant to the review. 
Results of captured studies were then synthesized and presented using a narrative approach.  
 
Risk of bias analysis 
Risk of bias was independently assessed by two authors (JK, NAK) using the Cochrane 
Collaboration Tool for Assessing Risk of Bias (Higgins et al., 2011). For each study, 
potential sources of bias were rated across six domains (selection, performance, detection, 





Database searching yielded 1,476 articles. After removing duplicates, 1,122 articles were 
eligible for title and abstract screening, with 1,026 articles not meeting eligibility criteria. 
Full-text screening was carried out for 96 articles, and reference chaining performed, yielding 
a total of 11 articles reporting on 9 unique studies for inclusion (Figure 1).  
 
Study characteristics  
Overall, the unique studies included 602 participants, with sample sizes ranging from 9-167 
participants, and children ranging in age from 1 day to 18 years. Publication dates ranged 
from 2008 to 2018, and all captured studies either reported the findings of a randomized 
controlled trial (RCT), or analysis of fecal samples and psychosocial data collected as part of 
an RCT (Table 1). Captured studies were undertaken in Europe (n=7), the United States 
(n=2), or Australia (n=2). Most articles (n=9; 82%) presented outcomes in infants with colic, 
with one study investigating the prevention of atopic dermatitis in infants, and one focused on 
children and adolescents with IBS.  
 
Risk of bias  
Overall, risk of bias was low or unclear in the captured studies (Table 2); however, risk of 
selective reporting bias (81%) and risk of attrition bias (63%) was high or unclear most trials. 
Allocation concealment and blinding of participants and outcomes generally posed low risk. 
Five trials were registered and one referenced a protocol. No study reported on missing data 




Microbiota interventions and analyses 
Almost all interventions involved probiotic supplementation, with the exception of one trial 
that tested a prebiotic (psyllium fiber) supplementation (Table 3). Approximately half of the 
probiotic studies (n=6) assessed Lactobacillus (L.) reuteri DSM 17938; the remaining studies 
used a variety of probiotic preparations, including multi-strain formulations (n=2), another 
single strain (L. rhamnosus GG ATCC 53103, n=1), and a synbiotic treatment (i.e., 
combination of probiotics and prebiotics, n=1). Studies varied in treatment duration (2 weeks 
to 6 months), and approach to microbiome analysis, including quantitative polymerase chain 
reaction (qPCR; n=8), culture-based techniques (n=2), and fluorescence in situ hybridization 
(FISH; n=1) to measure specific taxa and terminal restriction fragment length polymorphism 
(T-RFLP; n=2) or 16S ribosomal RNA sequencing using 454 pyrosequencing (n=3) to 
examine overall microbiome diversity or composition. 
 
Effects of intervention on the gut microbiota of infants with colic 
Baseline differences. Of the three studies that included a healthy control group, pre-treatment 
comparisons indicated differences in the microbiota of babies with colic. Lower levels of 
Bifidobacterium (Pärtty, Lehtonen, Kalliomäki, Salminen, & Isolauri, 2015), increased 
relative abundance of gram-negative anaerobes (Mentula, Tuure, Koskenala, Korpela, & 
Könönen, 2008), and increased prevalence of Escherichia [E.] coli and other indole-positive 
coliforms (i.e., Klebsiella oxytoca;(Mentula et al., 2008; Savino, Garro, Montanari, Galliano, 
& Bergallo, 2018) were found in babies with colic. Mentula et al. (2008) also found several 
(typically low-abundance) aerobic genera were undetectable in colicky infants 




Probiotic detection. Following treatment, four studies tested for the presence of the specific 
probiotic species in participant fecal samples. In three studies of L. reuteri, the strain was not 
detected in any untreated participants and was detectable in 45% to 92% of treated infants 
(Nation et al., 2017; Savino et al., 2010; Sung et al., 2014). In another study using a multi-
strain probiotic (Mentula et al., 2008), one of the major components of the formulation (L. 
rhamnosus GG) was detected in high concentrations in the feces of all probiotic-treated 
infants (n=5).  
 
Targeted analyses. Targeted culture- or PCR-based analyses of specific taxa of interest 
focused mainly on lactobacilli and bifidobacteria as examples of beneficial taxa and E. coli as 
an example of a putative pathogen (although E. coli Nissle 1917 strain is considered 
probiotic;(Wassenaar, 2016). Generally, lactobacilli and/or bifidobacteria were increased 
after intervention (Mentula et al., 2008; Pärtty et al., 2015; Savino et al., 2010; Savino et al., 
2018), with one exception (Baldassarre et al., 2018), where only a trend for increased 
lactobacilli was observed (p =0.053). Results for E. coli were less consistent; studies reported 
decreased levels in the intervention group (Savino et al., 2010), no difference between 
intervention and control groups (Savino et al., 2018; Sung et al., 2014), or increased rates of 
colonization in infants who received the probiotic (Nation et al., 2017). Enterococci (which 
include common commensal species) were found to be increased in one study (Mentula et al., 
2008), while another study found no change in levels of Clostridium butyricum (Savino et al., 
2010). 
 
Whole microbiome analyses. In terms of intervention effects on the overall gut microbiota of 
babies with colic, no differences between treatment and control conditions were observed in 
the five studies measuring alpha diversity (Fatheree et al., 2017; Nation et al., 2017; Sung et 
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al., 2014), beta diversity (Roos et al., 2013), or total bacterial load (Baldassarre et al., 2018). 
Fatheree et al. (2017) reported some post-treatment differences between groups at the family 
and genus levels, but no statistical analyses or beta-diversity plot were provided.  
 
Functional analyses. Two studies measured the functional output of the microbiome. 
Comparing samples from infants with colic to controls, Mentula et al. (2008), observed 
slightly elevated levels of unsaturated and branched fatty acids, and low levels of certain 
saturated and hydroxy cellular fatty acids, but no differences in fermentation products (i.e., 
gases and short-chain fatty acids). After intervention, the majority of probiotic-treated infants 
exhibited increased acetic acid and lactic acid production as well as reduced gaseous 
hydrogen production, while none of these parameters changed in placebo controls (the small 
sample size precluded statistical analysis). Using proton nuclear magnetic resonance, 
Baldassarre et al. (2018) also observed differential changes in the fecal metabolomics profile 
of probiotic-treated infants with colic; however, none of these metabolites were altered in the 
same way across studies (only acetate was altered by probiotic intervention in both, but in 
opposite directions), and neither study attempted to link the functional microbiome profile 
with infant outcomes.  
 
Effects of intervention on the gut microbiota of children with other medical conditions 
The two non-colic studies tested different interventions; one synbiotic (2 probiotic strains 
plus a prebiotic) for preventing atopic dermatitis (Roze et al., 2012), and one prebiotic 
(psyllium fiber) for IBS (Shulman et al., 2017). In the prebiotic study, overall microbiome 
composition did not change across the treatment period for the intervention or control group, 
regardless of the taxonomic level examined (from phylum down to operational taxonomic 
unit;(Shulman et al., 2017). In the synbiotic study, culture- and qPCR-based analyses 
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revealed lower levels of staphylococci and higher levels of lactobacilli in the synbiotic group 
after one month of treatment. These effects were maintained at 6 months (i.e., end of 
treatment), although only at the trend level for lactobacilli. There was also a trend towards 
increased bifidobacteria in the synbiotic-treated infants at 6 months (Roze et al., 2012). 
 
Mental health measures and outcomes  
Infant colic. The main outcomes in all studies of infant colic were changes in frequency of 
crying from baseline to intervention completion and follow-up, and amount of daily crying at 
a specified time-point between intervention and control groups. Crying data in two of the 
included studies were not collected independently, but were derived from larger trials. 
Specifically, results reported by Roos et al. (2013) were the same as those reported by Savino 
et al. (2010) and were therefore not included in this synthesis of crying outcomes. Nation et 
al. (2017) also assessed crying data included in an earlier publication (Sung et al., 2014), but 
the results of both studies have been included here because the data were analyzed differently 
in each case.  
 
All studies measured crying by asking parents to record daily crying time across the study 
period using a diary. One study also interviewed parents at intervention completion to 
estimate daily crying (Pärtty et al., 2015). Only four studies referenced use of a validated 
diary of infant crying (Fatheree et al., 2017; Pärtty et al., 2015; Savino et al., 2018; Sung et 
al., 2014). Two studies (Fatheree et al., 2017; Sung et al., 2014) also recorded infant fussing 
time, which was defined as “behavior that is not quite crying but not awake and content 
either” (Barr, Kramer, Boisjoly, McVey-White, & Pless, 1988). Two studies also assessed 




Across studies, there were no significant differences in baseline crying between intervention 
and control groups, and all studies reported a decrease in daily crying or fussing time in both 
groups across the study period. There were, however, mixed results in terms of whether 
probiotic intervention affected crying. Three studies reported no differences between 
treatment and placebo control groups (Fatheree et al., 2017; Mentula et al., 2008; Nation et 
al., 2017), and three studies reported a significant reduction in crying time in infants 
receiving probiotic treatment compared to the placebo (Baldassarre et al., 2018; Pärtty et al., 
2015; Savino et al., 2010; Savino et al., 2018). In terms of colic symptoms, two studies 
reported significant, but conflicting, differences between probiotic and placebo groups. Pärtty 
et al. (2015) found mothers reported a reduction in infant daily crying during their interview, 
but not when using the diary. Sung et al. (2014), somewhat surprisingly, found infants in the 
probiotic group fussed more than the placebo group at treatment end, although this difference 
was no longer present at 6-month follow-up and was not observed for crying. Study subgroup 
analyses revealed that the detrimental effect of probiotics was limited to formula-fed infants, 
whereas no treatment effect was observed in breast-fed infants.  
 
Of the two studies that assessed QOL, one found that probiotic intervention improved family 
QOL, as measured on a 10-point scale (Baldassarre et al., 2018), whereas the other found no 
differences on a more comprehensive, validated measure of child health-related QOL (Sung 
et al., 2014).     
 
Atopic dermatitis and irritable bowel syndrome. Like the colic studies, the study of infants 
with atopic dermatitis assessed daily crying time using a structured parent diary (Roze et al., 
2012) and found that infants who received a synbiotic supplement exhibited significantly less 
crying and more quiet behavior in the 3 days prior to a 1-month clinical visit (during 
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intervention); however, these differences were no longer observed at 6-months (post-
intervention), likely due to low levels of crying in both groups. Shulman et al. (2017) 
conducted a more comprehensive assessment of QOL and emotional and behavioral 
wellbeing in children with IBS; however, assessments were carried out at baseline only, so 
differences between children receiving psyllium fiber versus placebo were not tested. 
 
Associations between the gut microbiota and mental health outcomes 
Only two studies reported statistical analyses attempting to link the microbiota with 
psychosocial outcomes, both in the context of infant colic. Roos et al. (2013) found an 
increase in the abundance of Bacteroidetes over the treatment period in responders (infants 
with >50% reduction in colic symptoms) compared to non-responders. While not necessarily 
treatment-related, a higher proportion of probiotic-treated infants were classified as 
‘responders’. In the second study, Nation et al. (2017) found a positive correlation between L. 
reuteri colonization density and crying time in the subset of infants colonized by the 
bacterium.  
 
Effect of intervention on other physical health outcomes  
Across the captured RCTs, a range of physical outcomes were monitored, including pain, 
number of bowel movements, markers of inflammation in plasma, fecal calprotectin, 
presence of atopic dermatitis, and height and weight. In general, no significant differences 
were observed between intervention and control groups across the study period, with a few 
exceptions. First, prophylactic synbiotic treatment reduced risk for atopic dermatitis, although 
the significance of this effect was reduced to the trend level after adjustment for birth mode 
and family history of allergic disease (Roze et al., 2012). Second, prebiotic psyllium fiber 
reduced pain frequency, but not severity, compared to placebo in children with IBS (Shulman 
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et al., 2017). Third, Savino et al. (2018) reported elevated levels of fecal calprotectin in 
infants with colic compared to healthy controls at baseline, which declined over the 
intervention period only in the probiotic treatment group - although this was the only study 
(of five) to report an effect on fecal calprotectin. No negative treatment-associated effects 
were reported across the studies. 
 
DISCUSSION 
Research investigating the gut microbiome has increased exponentially in recent years, with 
studies showing that the microorganisms within our gastrointestinal tract can have important 
implications for human health and wellbeing. Generally, literature on the gut microbiome 
suggests complex and dynamic associations between microbiota and our physical and mental 
health. At the crossover of microbiome, physical, and mental health research, there is some 
evidence from that the microbiota contributes to mental health outcomes in adult medical 
populations (particularly with IBS; Kajander et al., 2008; Silk, Davis, Vulevic, Tzortzis, & 
Gibson., 2009; Yoon et al., 2013). This systematic review aimed to determine whether there 
is empirical evidence to directly support this association in pediatric populations, and to shed 
light on the associations between the microbiome and mental health in children with physical 
illness.  
 
Overall, we identified only 11 studies examining both the microbiome and psychological 
functioning in infants, children or young people with a medical condition. Unexpectedly, 
most of the identified studies examined infants, focused on one of only three physical health 
conditions, and all were clinical trials targeting the gut microbiome with either a prebiotic 
(psyllium fiber), probiotic, or synbiotic supplementation. Generally, no robust or consistent 
pattern emerged from the studies identified. Gut microbiome differences at baseline and 
14 
 
following intervention varied across studies, depending on the physical health condition and 
type of analysis conducted. Compared to healthy controls, studies showed that infants with 
colic have an atypical microbial profile (Mentula et al., 2008; Pärtty et al., 2015; Savino et 
al., 2018), including lower levels of Bifidobacterium (Pärtty et al., 2015), consistent with the 
extant literature (de Weerth, Fuentes, Puylaert, & de Vos, 2013; Rhoads et al., 2009). 
Intervention had no effect on measures of the whole microbiome in infants with colic or IBS 
(Baldassarre et al., 2018; Fatheree et al., 2017; Nation et al., 2017; Roos et al., 2013; 
Shulman et al., 2017; Sung et al., 2014), although this may be at least partly attributable to 
the shallow depth of resolution in analyses. Targeted analyses of lactobacilli and/or 
bifidobacteria suggested that the interventions enriched these beneficial taxa (Mentula et al., 
2008; Pärtty et al., 2015; Savino et al., 2010, 2018), while results were mixed for E.coli 
(Nation et al., 2017; Savino et al., 2010, 2018; Sung et al., 2014), which often acts as a 
pathogen. Findings on psychosocial functioning also varied, with only about half of the 
captured studies showing a positive effect of intervention on measures of infant distress 
(namely, crying).  
 
The main question this review sought to address was whether there is evidence that gut 
microbiota are associated with mental health outcomes in children with physical illness. We 
identified only two studies examining microbiome-mental health associations (Nation et al., 
2017; Roos et al., 2013), demonstrating that research investigating the role of the microbiome 
in pediatric physical and mental health is extremely limited (Bai, Behera, & Bruner, 2018). 
Although the findings of these studies are of interest - with one set of results showing a link 
between beneficial Bacteroidetes and greater reductions in infant crying across the 
intervention period (Roos et al., 2013) - the evidence is clearly preliminary and precludes 
firm conclusions or clinical recommendations. Thus, while the gut microbiome has exciting 
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potential to teach us more about the links between child physical and mental health, the 
findings of this review show much research is needed to substantiate these associations.  
 
Limitations of captured studies and the current review  
Some of the variability in findings across studies may be explained by microbiome factors, as 
well as differences in study design, intervention, measures, and time-points analyzed. 
Although most studies collected and analyzed fecal samples at baseline, analyses were 
generally not sufficiently powered or detailed to allow identification of potential pre-existing 
individual differences that might predict treatment response. As an example, one of the 
interventions (psyllium fiber) was previously shown to act as a prebiotic only in individuals 
with low baseline levels of bifidobacteria (Elli, Cattivelli, Soldi, Bonatti, & Morelli, 2008). 
Many of the microbiome and psychological analyses were limited by small sample sizes and 
single points of data collection (usually at treatment completion). These factors likely 
contributed to the paucity of data on interactions between the microbiome and psychological 
outcomes. Differences in baseline microbiome composition and microbiome response to 
treatment (e.g., colonization by introduced probiotic species) are factors that may contribute 
to individual differences in physical and mental health outcomes, as observed in two studies 
within the present dataset (Nation et al., 2017; Roos et al., 2013), as well as in other cases 
(e.g., microbiome modulation of cancer therapy efficacy;(Bashiardes, Tuganbaev, Federici, & 
Elinav, 2017; Gopalakrishnan, Helmink, Spencer, Reuben, & Wargo, 2018). 
 
Importantly, a number of studies included participants who varied across factors known to be 
key determinants of infant microbiome composition, including birth mode (vaginal vs. 
Cesarean section;(Chu et al., 2017; Dominguez-Bello et al., 2010) and diet (breast- vs. 
formula feeding;(Ho et al., 2018), and generally these variables were not accounted for in 
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analyses. These factors are particularly important in the studies of infants with colic, given 
the effects of birth mode are most potent in early life (Chu et al., 2017; Hill et al., 2017) and 
there is now evidence that formula feeding reduces the efficacy of probiotic interventions for 
colic (Sung et al., 2018). 
 
Further, the techniques used to assess the microbiome in most of the captured studies were 
outdated. Most studies relied on culture-based methods or qPCRs targeting selected bacterial 
taxa, and only three studies used 16S rRNA sequencing, which is generally considered the 
current minimum standard for microbiome studies. In fact, the field is rapidly moving 
towards the use of shotgun metagenomics sequencing (Jovel et al., 2016; Ranjan, Rani, 
Metwally, McGee, & Perkins, 2016), a technique not used in any of the captured studies. 
Shotgun sequencing is more expensive than 16S but provides superior resolution for profiling 
of the microbiome down to the species, and even the strain, level. In contrast, 16S is currently 
reliable only to the genus level, making it difficult to differentiate beneficial from pathogenic 
taxa. If the aim of conducting microbiome analyses is to differentiate disease or treatment 
profiles and identify the functional relevance of any observed changes, then much greater 
specificity is needed. The need for in-depth analyses is supported by the findings of the 
current set of studies, where differences in the representation of specific species were 
observed using targeted culture-based techniques and qPCR, while metabolomics and short-
chain fatty acid analyses hinted at differences in the functional capacity of the microbiome 
after intervention.  
 
Like the microbiome assessments, measures used to assess mental health or psychological 
functioning in the captured studies were limited, and no studies specifically assessed mental 
health outcomes such as anxiety or depression. Of the studies that assessed crying as a 
17 
 
measure of colic symptoms and infant distress, only about half referenced using a validated 
diary, making it difficult to assess data quality in the remaining studies. Other measures 
lacked specificity, with one study using only a single 10-point scale to assess family QOL. 
While many psychometric measures ask participants for retrospective or general accounts of 
factors such as QOL, mood and anxiety, for studies reliant on accurate daily accounts of 
behavior (e.g., crying), it is critical to improve the quality and specificity of measures so as to 
minimize error and recall bias.  
 
This review had several limitations. First, the heterogeneity of methodologies used across the 
captured studies made it difficult to pool results and precluded meta-analysis. Second, there 
was an overrepresentation of infant colic, limiting the generalizability of findings, and 
making it difficult to draw conclusions on the current state of the microbiome and mental 
health outcomes in other medical conditions. Likewise, most of captured studies focused on 
medical conditions of a non-critical or acute (rather than chronic) nature, and investigated 
outcomes in infants, meaning the results presented here may not generalize to critical or 
chronic medical conditions, nor to older children and adolescents.  
 
Future research recommendations  
Overall, there is much room for improvement regarding the design, analysis, and 
interpretation of studies investigating the role of the microbiome in child physical and mental 
health. To elucidate the functional role of the microbiome in this field, recommendations for 
future studies include: (i) consistent use of more detailed and robust microbiome analyses, 
including contemporary sequencing techniques (i.e., 16S and shotgun metagenomics), (ii) use 
of advanced computational and statistical modeling, (iii) stronger justification for treatment 
length, dosage, and probiotic strain used, (iv) use of validated instruments to measure mental 
18 
 
health and psychological functioning, and (v) larger sample sizes and specific statistical 
analyses of interactions between the microbiome and mental health outcomes. This will likely 
require strong interdisciplinary collaboration between microbiome experts (microbiologists, 
bioinformaticians), clinicians (e.g., psychologists, physicians), and researchers specializing in 
mental health and psychobiological development.     
 
This review highlights the large gap in our knowledge of the connections between the gut 
microbiome and physical and mental health in pediatric populations – with this gap being 
even larger for children and young people with critical or chronic medical illness. Pleasingly, 
efforts are underway to investigate the effect of probiotic treatment on both the microbiome 
and health-related QOL in children with chronic conditions, such as cystic fibrosis (Coffey, 
Garg, Homaira, Jaffe, & Ooi, 2018). Our group is also investigating associations between the 
gut microbiome, HPA axis, and neurobiological and psychological factors in children and 
adolescents with complex congenital heart disease.   
 
CONCLUSIONS 
As the field moves forward, it will be critical to gain a better understanding of the baseline 
microbiome characteristics that can influence treatment (e.g., deficiencies in particular 
species) and mental health outcomes in pediatric populations. This would fit with the current 
push towards using the microbiome to inform and enhance personalized medicine approaches 
(Jobin, 2018; Kuntz & Gilbert, 2017; Petrosino, 2018). Targeting the gut microbiome during 
early development could have critical implications for disease prevention and management, 
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Figure 1. PRISMA diagram illustrating the systematic search process. 
 
Table 1. Summary of article characteristics (N=11). All captured studies used a randomized 
controlled trial (RCT) design. 
 
Table 2. Risk of bias in randomized controlled trials, rated using the Cochrane Risk of Bias 
tool. For each domain, studies were rated as having a high (-), low (+), or unclear (?) risk of 
bias using the Cochrane Risk of Bias tool. 
 
Table 3. Summary of key findings across all captured articles (N=11), as relevant to this 
review. 
 
 
